Citigroup Initiates Coverage On Iambic Therapeutics with Buy Rating, Announces Price Target of $22
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsInitiationPrice Target
Citigroup analyst Geoff Meacham initiates coverage on Iambic Therapeutics (NASDAQ:IAM) with a Buy rating and announces Price Target of $22.
Citigroup analyst Geoff Meacham initiates coverage on Iambic Therapeutics (NASDAQ:IAM) with a Buy rating and announces Price Target of $22.